Shares of Alexion Pharmaceuticals Inc. were halted late Wednesday after the New Haven, Conn., company said it will delay filing its third-quarter report due to an ongoing investigation into certain sales practices following allegations by a former employee. The investigation has not identified instances where orders of Alexion’s drug Soliris were not placed by customers for patients or any facts that require the company to update its previously reported historical results, Alexion said. Shares of Alexion ended the regular trading session up 6.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News